Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ALXO

ALXO - ALX Oncology Holdings Inc. Stock Price, Fair Value and News

$1.38-0.12 (-8.00%)
Market Closed

Price Targets

ALXO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALXO Price Action

Last 7 days

-6.1%

Last 30 days

9.5%

Last 90 days

-11.0%

Trailing 12 Months

-9.8%

ALXO RSI Chart

ALXO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ALXO Valuation

Market Cap

74.8M

Price/Earnings (Trailing)

-0.69

Price/Sales (Trailing)

63.3

EV/EBITDA

-0.43

Price/Free Cashflow

-0.77

ALXO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ALXO Fundamentals

ALXO Revenue

Revenue (TTM)

1.2M

ALXO Earnings

Earnings (TTM)

-108.0M

Earnings Growth (Yr)

27.89%

Earnings Growth (Qtr)

14.66%

ALXO Profitability

EBT Margin

-11408.63%

Return on Equity

-241.09%

Return on Assets

-130.57%

Free Cashflow Yield

-130.22%

ALXO Investor Care

Shares Dilution (1Y)

2.80%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20204.4M3.7M2.4M1.2M
201903.0M3.9M4.8M
20180002.1M
Get all data in R, Python etc through our Historical Stock Data APIs

About ALX Oncology Holdings Inc.

ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer. The company's pre-clinical program focuses on the development of ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has collaboration agreements with Merck for a Phase 2 trial evaluating evorpacept in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial for the treatment of HER2-expressing breast cancer and other solid tumors; Tallac Therapeutics, Inc. for the development of a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses; and the Quantum Leap Healthcare Collaborative to sponsor and manage a Phase 1 trial to evaluate evorpacept in combination with fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive and HER2-low breast cancer. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
 CEO
 WEBSITEalxoncology.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES72

ALX Oncology Holdings Inc. Frequently Asked Questions

ALXO is the stock ticker symbol of ALX Oncology Holdings Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of ALX Oncology Holdings Inc. is 74.82 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ALXO's fair value in chart for subscribers.

The fair value guage provides a quick view whether ALXO is over valued or under valued. Whether ALX Oncology Holdings Inc. is cheap or expensive depends on the assumptions which impact ALX Oncology Holdings Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ALXO.

As of Wed Jan 28 2026, ALXO's PE ratio (Price to Earnings) is -0.69 and Price to Sales (PS) ratio is 63.3. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ALXO PE ratio will change depending on the future growth rate expectations of investors.